- Report
- May 2023
- 180 Pages
Global
From €5679EUR$5,950USD£4,758GBP
- Report
- November 2023
- 150 Pages
Global
From €4629EUR$4,850USD£3,878GBP
- Report
- February 2024
- 182 Pages
Global
From €4295EUR$4,500USD£3,598GBP
- Report
- June 2023
- 116 Pages
Global
From €4295EUR$4,500USD£3,598GBP
- Report
- February 2024
- 180 Pages
Global
From €4742EUR$4,969USD£3,973GBP
- Report
- January 2024
- 190 Pages
Global
From €4295EUR$4,500USD£3,598GBP
- Report
- August 2022
- 120 Pages
Global
From €4533EUR$4,750USD£3,798GBP
- Report
- October 2023
- 190 Pages
Global
From €4295EUR$4,500USD£3,598GBP
- Report
- March 2024
- 200 Pages
Global
From €3961EUR$4,150USD£3,318GBP
- Report
- December 2023
- 157 Pages
Global
€4767EUR$4,995USD£3,994GBP
- Report
- November 2023
- 67 Pages
China
From €1718EUR$1,800USD£1,439GBP
- Report
- November 2023
- 93 Pages
China
From €1718EUR$1,800USD£1,439GBP
- Report
- May 2023
- 103 Pages
Global
From €3500EUR$3,929USD£3,035GBP
- Report
- November 2023
- 205 Pages
China
From €3818EUR$4,000USD£3,199GBP

Bisphosphonates are a class of drugs used to treat musculoskeletal disorders, such as osteoporosis, Paget's disease, and bone metastases. They work by inhibiting the activity of osteoclasts, the cells responsible for breaking down bone. Bisphosphonates are typically administered orally or intravenously, and are available in both generic and branded forms.
Bisphosphonates are widely used in the treatment of musculoskeletal disorders, and are often prescribed in combination with other drugs. They are generally well-tolerated, with few side effects. However, long-term use of bisphosphonates has been associated with an increased risk of atypical femur fractures.
The bisphosphonates market is highly competitive, with a number of major players. These include Merck & Co., Novartis, Amgen, Sanofi, and Pfizer. Other companies in the market include Eli Lilly, GlaxoSmithKline, and Teva Pharmaceuticals. Show Less Read more